Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics set to begin phase II trial of PQ Grass hay fever treatment “imminently”

The allergy vaccine specialist has received regulatory approval to start the phase II trial
hay fever sufferer
AGY reckons PQ Grass, if it gets through the clinic, could generate sales of up to US$300mln a year

Allergy Therapeutics plc (LON:AGY) moved highert today on news it is set to kick off the phase II clinical trial of its hay fever treatment “imminently” after the pharma group got the necessary approvals from authorities.

In late afternoon trading, the firm's shares were up 2.8%, or 0.88p at 32.38p.

The AIM-quoted group believes PQ Grass has the potential to cure grass pollen-induced hay fever, or allergic rhinitis as it’s known in medical circles.

The trial will take place in Germany, Poland and Austria and will involve around 440 patients.

Results from the study are expected in the second half of next year.

Could be worth US$300mln a year to AGY

Should it pass through the clinical stage successfully, Allergy expects the US market to be the main market for the product.

That market alone is estimated to be worth around US$2bn a year and the company is looking at generating peak annual sales of US$300mln from PQ Grass.

If it does get approval, it will be the first subcutaneous (a short needle which injects the drug under the skin) immunotherapy registered in the States.

“This revised Phase II trial will prepare the ground for entry in to the high value US market in which PQ Grass has the potential to become a convenient, best in class, ultra-short course subcutaneous immunotherapy,” said chief executive Manuel Llobet.

“We look forward to reporting headline data next year as we advance this product.”

 -- Adds share price --

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use